Research - Raymond Lance, MD

Clinical Research

1. SWOG #9217 Chemoprevention of prostate cancer with Finasteride (Proscar), Phase III, intergroup. 2.
2. SWOG #8794 Treatment of pathologic stage C carcinoma of prostate with adjuvant radiotherapy.
3. SWOG #9450 Prostate cancer intervention versus observation trial (PIVOT): A randomized trial comparing radical prostatectomy versus palliative expectant management for the treatment of clinically localized prostate cancer.
4. MAMC #97120 A randomized, double blind study (with open-label treatment extension) to evaluate the efficacy and safety of Viagra (Sildenafil) in erectile dysfunction.
5. MAMC #98092 Comparison of quality of life (QOL) differences between radical retropubic (RRP) and radical perineal prostatectomy (RPP) for clinically localized prostate cancer.
6. MAMC #98092 Multicenter prostate cancer database of outcomes, prognostic analysis, and patterns of care. Center for Prostate Disease Research (CPDR).
7. MAMC #95134 Comparative study of the clinical efficacy of two dosing regimens of Eulexin: 250 mg Q8h vs 500mg QD.
8. MAMC #99003 A randomized double-blind comparative trial of bicalutamide (Casodex) 150 mg monotherapy versus placebo in patients with a rising PSA after radical prostatectomy for prostate cancer.
9. MAMC #98114 Uniformed Services comprehensive database and tissue repository for the study of epidemiology, detection, natural history, and management strategies for prostate cancer.
10. MAMC #318-319 Tumor suppressor gene analysis and family study of patients with multiple genitourinary primary malignancies.
11. ECOG #2805 A Randomized, Double-Blind Phase III Trial of Adjuvant Sunitinib versus Sorafenib versus Placebo in Patients with Resected Renal Cell Carcinoma. 2007
12. Abbott Molecular, Inc: Validation of the Autofish™ Urovysion™; Bladder Cancer Kit on the Biogenex Xmatrx™ Automated Slide Staining System. 2008
13. AEterna Zentaris Inc: Cetrorelix pamoate (AEZS-102) in patients with symptomatic BPH: an open-labeled safety and efficacy assessment study. 2008
14. Amgen: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3 Study of Denosumab on Prolonging Bone Metastasis-Free Survival in Men with Hormone-Refractory Prostate Cancer. 2008
    AMS PE0603: A Prospective Clinical Study for GreenLight HPS™ in the Treatment of Obstructive Benign Prostatic Hyperplasia (BPH). 2008
15. Argos Therapeutics Inc. A Phase II Study Testing the Safety and Activity of AGS-003 as an Immunotherapeutic in Subjects with Newly Diagnosed Advanced Stage Renal Cell Carcinoma in Combination with Sunitinib. 2008
16. Astellas 9785-CL-0222 [MDV3100] A Randomized, Double-blind, Phase II, Efficacy and Safety Study of MDV3100 vs. Bicalutamide in Castrate Men with Metastatic Prostate Cancer (Sub-I)
17. AstraZeneca ZD4054: A Phase III, Randomised, Double-blind Study to Assess the Efficacy and Safety of 10 mg ZD4054 versus Placebo in Patients with Hormone-resistant Prostate Cancer and Bone Metastasis who are Pain Free or Mildly Symptomatic.
18. Bioniche HIS-0611-09692: A Phase III, open-label, multi-center study of the efficacy and safety of MCC in the treatment of patients with non-muscle invasive (superficial) bladder cancer at high risk of progression and who are refractory to BCG (Sub-I)
19. Cougar Biotechnology COU-AA-301: A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Patients with Metastatic Castration-Resistant Prostate Cancer (CRPC) Who Have Failed Docetaxel-Based Chemotherapy (Sub-I)
20. Cougar Biotechnology COU-AA-302: A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients with Metastatic Castration-Resistant Prostate Cancer (Sub-I)
21. Cougar Biotechnology 212082PCR3001 An Open Label Study of Abiraterone Acetate in Subjects with Metastatic Castration Resistant Prostate Cancer who Have Progressed After Taxane-based Chemotherapy (Sub-I)
22. Dendreon Corp. A randomized, double-blind, placebo controlled phase 3 trial of immunotherapy with autologous antigen presenting cells loaded with PA2024 (Provenge, APC8015) in asymptomatic subjects with Gleason sum £ 7, metastatic, androgen independent prostatic adenocarcinomas. Protocol 9902b (Sub-I)
23. Dendreon Corp. Autologous pap-loaded dendritic cell vaccine (APC8015, provenge) in patients with non-metastatic prostate cancer who experience psa elevation following radical prostatectomy: a randomized, controlled double-blind trial. Protocol P-11 (PI)
24. Dendreon Corp. An open-label study of sipuleucel-T in men with metastatic castrate resistant prostate cancer. Protocol P09-1 (PI)
25. Dendreon Corp. A randomized, multicenter, single blind study in men with metastatic androgen independent prostate cancer to evaluate sipuleucel-T manufactured with different concentrations of PA2024 antigen. Protocol P07-2 (PI)
26. Dendreon Corp. An open label, single arm trial of immunotherapy with autologous antigen presenting cells loaded with pa2024 (APC 8015F) for subjects with objective disease progression and disease-related pain on trial dD9902 part B. Protocol PB01 (PI)
27. Dendreon P10-3: PROCEED – A Registry Of Sipuleucel-T Therapy In Men With Advanced Prostate Cancer (PI)
28. Dendreon N10-1: A Randomized, Phase 2, Open-Label Study Evaluating Dn24-02 As Adjuvant Therapy In Subjects With High Risk Her2+ Urothelial Carcinoma (PI)
29. Dendreon P11-3: A Randomized, Open-Label, Phase 2 Trial Of Sipuleucel-T With Concurrent Versus Sequential Administration Of Abiraterone Acetate Plus Prednisone In Men With Metastatic Castrate Resistant Prostate Cancer (PI)
30. Ferring Pharmaceuticals, Inc. A Randomized, Controlled, Open-Label Trial of Degarelix Intermittent Therapy vs. Continuous Androgen Deprivation Therapy with Leuprolide or Degarelix in Patients with Carcinoma of the Prostate with Biochemical Failure after Localized Therapy, FE 200486 CS37 (Sub-I), 2009.
31. Ferring FE200486 CS35: An Open-Label, Multi-Centre, Randomized, Parallel-Arm One-Year Trial, Comparing the Efficacy and Safety of Degarelix Three-Month Dosing Regimen with Goserelin Acetate in Patients with Prostate Cancer Requiring Androgen Deprivation Therapy (Sub-I)
32. Ferring FE200486 CS30: A Randomized, Parallel Arm, Open-Label Trial Comparing Degarlix with Goserelin Plus Anti-Androgen Flare Protection (Bicalutamide), in Terms of Prostate Size Reduction in Prostate Cancer Patients of Intermediate-to-High Risk, Who Require Neoadjuvant Hormone Therapy Prior to Radiotherapy (PI)
33. Glaxo-Smith-Kline (GSK) AVO108943 A Randomized Double-Blind Parallel Group Study Comparing Casodex 50mg plus Placebo to Casodex 50mg plus dutasteride 3.5mg Administered for 18 months to Men with Prostate Cancer Who Have Failed First-Line Androgen Deprivation Therapy (Assessed by Rising PSA) Followed by a Two-Year Extension Phase. 2007
34. GTx, Inc 200705: Phase II, open label, dose finding study of the effect of GTx-758 on total and free testosterone levels in men with prostate cancer compared to a luteinizing hormone releasing hormone agonist (Sub-I)
35. GTx, Inc 200707: Open label study of the effect of GTx-758 on serum PSA and free testosterone levels in men with castration resistant prostate cancer and maintained on androgen deprivation therapy (Sub-I)
36. GP Pharma GP/C/05/PRO: Efficacy and Safety of a New Leuprolide Acetate 22.5 mg Depot Formulation in the Treatment of Prostate Cancer (Sub-I)
37. Spectrum Pharmaceuticals, Inc. (protocol SPI-1011) A Phase 3 International, Multicenter, Double-Blind, Placebo-Controlled, Randomized Trial Evaluating the Efficacy and Safety of Multiple Instillations of Intravesical Apaziquone vs. Placebo in Patients with Low-Intermediate Risk Non-Muscle Invasive Bladder Cancer (NMIBC)
38. GlaxoSmithKline VEG113387: A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy and safety of pazopanib as adjuvant therapy for subjects with localized or locally advanced RCC following nephrectomy (PI)
39. Millennium Pharma C21004 A Phase 3, Randomized, Double-blind, Multicenter Trial Comparing Orteronel (TAK-700) Plus Prednisone with Placebo Plus Prednisone in Patients with Chemotherapy-Naïve Metastatic Castration-resistant Prostate Cancer (Sub-I)
40. OncoMethylome Sciences, Inc. Gene Metylation Testing in Urines from Patients Undergoing: Initial diagnostic Testing for Bladder Cancer, Monitoring for Bladder Cancer Disease Recurrence, or Receiving Immunomodulatory Treatment. (PI)
41. Sanofi-Adventis: XRP6976J/3503 A Multicenter, Open-Label, Randomized, Phase III, 2-Arm Deprivation with Leuprolide, +/- Docetaxel for Clinically Asymptomatic Prostate Cancer Subjects with a Rising PSA Following Definitive Local Therapy (PI). 2007
42. Spectrum Pharmaceuticals, Inc. (protocol SPI-611) A Multicenter, Randomized Placebo-Controlled, Double-Blind, Phase 3 Trial of Single-Dose Intravesical EOquin as a Surgical Adjuvant Instilled in the Early Postoperative Period in Patients Undergoing Transurethral Resection for Noninvasive Bladder Cancer. (Sub-I)
43. Watson Labs TRE1001: Randomized Crossover Trial to Assess the Tolerability of GnRH Analogue Administration in Patients with Advanced Prostate Cancer (Sub-I)

Basic Science Research

1. MAMC #94051 Insulin-like growth factor binding protein-related protein 1 and suppression of prostate carcinogenesis.
2. MAMC #97097 Telomerase in urine as a diagnostic and surveillance marker of transitional cell carcinoma.
3. MAMC #94051 Regulation and proliferation of prostate epithelial cells mediated by Vitamin D and IGF-binding proteins
4. MAMC #94051Use of Telomerase catalytic protein component constructs to create immortalized prostate cancer cell-lines from fresh tissue explants.
5. MAMC #95104 Telomere length and telomerase activity in human testicular cancer.
6. MAMC #97129 Correlations between free and total PSA, prostate-specific membrane antigen, and sex-hormone binding globulin across the spectrum of prostate disease.
7. MAMC #97097 Serum telomerase RNA levels in the serum of normal male controls, men with BPH, men with localized, and metastatic prostate cancer.
8. MAMC #404 Insulin-like growth factor- I receptor number in transitional cell carcinoma of the bladder.
9. MAMC #99109 Limits of detection of circulating prostate and bladder cancer cells using telomerase reverse transcriptase (H-TERT) mRNA detection by reverse transcriptase polymerase chain reaction (PCR).
10. MAMC #201140 Intratumoral treatment of human prostate cancer xenografts in nude mice by polymeric gel delivery of yttrium-90 with and without taxol.
11. EVMS #00031 Renal Cell Carcinoma Biomarker Discovery Project. 2007
12. EVMS #0037 Prostate Cancer Micrometastasis Biomarker Discovery Project. 2007
13. EVMS #0109 Determination of the predictive value of Chromogranin-A immunostaining of prostate biopsy specimens, and Chromogranin-A levels in serum and urine in men with micrometastatic prostate cancer. 2007
14. EVMS #0343 Detection of unique protein expression in expressed prostate secretions of men undergoing prostate biopsy. 2007
15. EVMS – Protein expression in radical prostatectomy specimen lavage immediately after resection during Laparoscopic Radical Prostatectomy: margin status biomarker discovery. 2007
16. EVMS #0119 (SPORE) Urinary Bladder Cancer Biomarker Discovery Project. 2008
17. EVMS #0171 Urinary Bladder Cancer Immunochemistry and Genomic Analysis Using Paraffin-Embedded Formalin Fixed Tissues. 2008
18. EVMS #0180 (SNPs) Whole genome-wide genetic alterations in Prostate Cancer: impact of disease severity and modifiable risk factors. 2008
19. EVMS #0189 Prostate Cancer Immunochemistry and Genomic Analysis Using Paraffin-Embedded Formalin Fixed Tissues. 2008
20. EVMS – Prostate Active Surveillance Study. 2010
21. EVMS – Clinical and Molecular Risk Factors Associated in the Development of Micrometastasis in Renal Cell Carcinoma. 2011